HLT and RunDong Pharma Announce Strategic Partnership to Pioneer a New Model in Drug Development

On August 29, Happy Life Technology (HLT) and Rundo Pharmaceutical Research & Development (Shanghai) Co., Ltd. successfully held a strategic cooperation signing ceremony in Shanghai, announcing that both parties would leverage their respective strengths by combining HLT’s innovative big data technologies with Rundo’s extensive experience in traditional clinical research. This strong partnership aims to drive the transformation of China’s CRO industry, accelerate the alignment of Chinese clinical research with international advanced standards, and support Chinese pharmaceutical companies and their products in going global.

Mr. Xu Jiming, Co-founder of HLT; Dr. Tan Qian, Chief Medical Officer of HLT; Dr. Shen Lijun, Chief Biostatistician of HLT; Dr. Xiong Tengbin, Director of Pharmacoeconomics and Real-World Study Solutions at HLT; Mr. Huang Shengxuan, Managing Director of Sunshine Ronghui; Mr. Jiang Shixin, Chairman of R&D Pharma; Mr. Jiang Hai, Managing Director of R&D Pharma; Ms. Zhao Fu, General Manager of Shoujia, an SMO subsidiary of R&D Pharma; Mr. Xu Rensong, General Manager of the Nantong Subsidiary; Mr. Zhang Lifeng, Director of the Project Management and Outsourcing Department; Mr. Li Jianfei, Director of the Clinical Operations Department; Mr. Wang Zuozhen, Director of the Biostatistics Department; Mr. Li Peng, Director of the Regulatory Affairs Department; Ms. Dai Feiyi, Director of the Planning and Finance Department; and Mr. Liu Rui, Director of the Overseas Department, among other leaders from both parties, jointly attended the signing ceremony.

Signed Image

As a leading enterprise in intelligent medical data technology, HLT holds significant advantages in AI-empowered innovative pharmaceutical research. Since its inception, HLT has been deeply committed to the study of big medical data technologies, developing unique capabilities in data structuring and standardization. The company has built multiple carriers and platforms featuring innovative technological applications, serving nearly 100 top-tier hospitals in China, government agencies such as the National Medical Products Administration (NMPA), and numerous large multinational pharmaceutical companies, thereby providing customers with comprehensive intelligent medical data technology solutions. Currently, HLT has established an ever-expanding ecosystem for medical data applications, incorporating over 3,000 data intelligence mining and processing models across specialized disease areas, thus facilitating the development of artificial intelligence technologies within the healthcare industry.

Rundong Pharma, established in 2004, is a leading, standardized, and large-scale Contract Research Organization (CRO) in China. With a professional and dedicated team and extensive clinical research resources, the company specializes in outsourced clinical drug research, providing high-quality, efficient one-stop clinical research services. As a primary initiator and promoter of the China CRO Union (CROU), Rundong Pharma currently serves as the chairing entity of the alliance. It is the first CRO company in China’s CRO industry to achieve certification combining the ISO 9001:2008 Quality Management System with CRO industry standards. Since its inception, the company has undertaken more than 700 clinical research projects, earning a strong reputation within the industry. Currently, Rundong Pharma operates a Beijing branch and five subsidiaries, with offices or stationed personnel in nearly 60 cities, including Guangzhou and Hangzhou. Its subsidiaries include the Nantong subsidiary (pharmacovigilance and biostatistics/data management), the Shoujia subsidiary (Site Management Organization for clinical trials), the Japanese subsidiary (Medison Pharmaceutical Japan Co., Ltd.), and a Phase I Clinical Trial Center. The establishment of a U.S. subsidiary is also actively being planned.

Xu Jiming, Co-founder of HLT, stated, “Amid the wave of technological innovation, big data and AI technologies are driving significant changes in the pharmaceutical industry. To date, HLT has established an EDC product line validated by NNIT, an international professional services firm, and boasts a world-class academic team specializing in clinical science and statistical methodology. We possess particular expertise and competitive advantages in real-world evidence (RWE) studies. We believe this strategic partnership will deliver unique value to both companies, and we are committed to working together to provide enhanced services for our clients.”

Huang Shengxuan, Managing Director of Sunshine Convergence, stated that the collaboration between the two parties will establish a new CRO service model tailored to China’s unique characteristics. Jiang Hai, Managing Director of Rundo Pharma, remarked, “Over the past 15 years since its establishment, Rundo Pharma has been committed to providing one-stop, comprehensive, high-quality, and efficient clinical research outsourcing services. Through this partnership with HLT, Rundo Pharma will work hand in hand with HLT to optimize existing clinical research management models and systems. We will engage in technical collaboration, system optimization, resource integration, and cost and risk control across all levels of clinical research in a novel manner. By fostering innovation while building on our traditional strengths, we will continue to deliver high-quality drug clinical research outsourcing services to clients both domestically and internationally, thereby driving the development of China’s pharmaceutical industry.”

This time, HLT and Rundo Pharma have entered into a strategic partnership to form a joint team that leverages complementary strengths and explores optimal models for cross-sector collaboration. Their shared commitment to enhancing the quality, efficiency, standardization, and advancement of clinical research will undoubtedly set a benchmark for driving AI-enabled drug development deeper into the industry, provide successful case studies for the tight integration of clinical drug development with AI, lead innovative development in the pharmaceutical sector, help more outstanding Chinese pharmaceutical companies and drugs go global, and ultimately benefit patients in China and worldwide.